BioSight
Companies
Acumen Pharmaceuticals, Inc. logo

ABOS

NASDAQNEWTON, MA
Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals develops monoclonal antibody therapies targeting amyloid-beta oligomers for neurodegenerative diseases, with sabirnetug as its lead candidate currently in clinical testing. Sabirnetug is being evaluated in the ALTITUDE-AD trial for Alzheimer's disease, with potential advantages in safety and efficacy compared to other anti-amyloid antibodies in development. Acumen is also collaborating with JCR Pharmaceuticals on an amyloid-beta oligomer-targeted Enhanced Brain Delivery therapy candidate.

Price history not yet available for ABOS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar